Few supplements have ridden the longevity hype cycle harder than NMN and NAD+ boosters. Popularized by Harvard geneticist David Sinclair, author of Lifespan, who has publicly described taking NMN himself, and embraced by the biohacker community, these compounds promise to restore a molecule that declines with age and, by doing so, slow aging itself. The story is elegant. The evidence is complicated. Here is where things actually stand.
NMN and NAD+: The Evidence Story So Far
Tap each phase to expand what the article reports. The article names no single pivotal trial, so this timeline follows the research story, not a study calendar.
Foundation NAD+ declines with age
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. It drives energy metabolism and fuels enzymes involved in DNA repair and stress responses, including the much-discussed sirtuins. The key fact driving the entire field: NAD+ levels decline with age in animal models, with evidence of similar declines in human tissues. This decline is associated with reduced mitochondrial function, impaired DNA repair, and other hallmarks of aging. The logic is straightforward: restore NAD+ to youthful levels, and you might restore youthful cellular function. A reasonable hypothesis, and reasonable hypotheses still need testing.
Mouse era Genuinely exciting animal results
In mice, NAD+ precursor supplementation produced striking results: improved mitochondrial function, better metabolic health, enhanced physical endurance, improved markers of vascular aging, and in some models, extended healthspan. Researchers described these findings as among the more promising in aging science. Major research institutions invested heavily. This is why serious longevity scientists, not just supplement marketers, pay attention. But mice are not people: countless interventions that rejuvenated mouse tissues have failed in humans. The animal data justifies human trials. It does not justify conclusions.
The pivot NMN and NR raise NAD+ in humans
You cannot simply take NAD+ as a pill and expect it to reach cells intact; it is a large molecule with poor oral bioavailability. Instead, the industry sells precursors the body converts into NAD+: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both have been shown in multiple randomized, placebo-controlled human trials to raise NAD+ levels in blood in a dose-dependent manner. That part is established. The much harder question is whether raising NAD+ improves anything that matters.
Human trials Raised NAD+, unclear benefits
Beyond the biomarker, results are modest and mixed. Some trials reported improvements in insulin sensitivity, muscle function, or markers of cardiovascular health, particularly in older adults or people with metabolic concerns. Others found no significant difference from placebo. No human trial has demonstrated extended lifespan or clearly slowed aging, and given the timescales involved, none could have yet. The gap between “raises a blood marker” and “makes you age slower” remains unbridged.
Safety Reassuring so far, with asterisks
- Short-term human trials generally found NMN and NR well tolerated, with side effect profiles similar to placebo.
- Long-term safety data in humans is essentially nonexistent.
- Some researchers have raised theoretical concerns: NAD+ fuels all cells, and there are open scientific questions about whether raising it could influence processes involved in cancer biology. Hypotheses, not findings.
- Regulatory whiplash: NMN’s status as a dietary supplement has been contested, with regulators at one point moving to exclude it from the supplement category before the situation shifted again.
Now Watch the research, not the price tag
NMN and NR cost many times more than basic vitamins, while the proven human benefit is currently limited to raising a blood biomarker. Price should scale with proof, and the proof has not caught up with the price. Most aging researchers consider NAD+ biology a legitimate research area and are cautiously optimistic it will eventually yield real interventions, but very few would say the evidence justifies expensive daily supplementation for longevity. Watch the large, long-term trials underway. If they show durable improvements in hard outcomes like physical function or cardiovascular events, the calculus changes. Until then: a “watch the research” category, not a “buy the bottle” category.
This timeline summarizes the article’s narrative of the field. It is for information only and is not medical advice. Talk to your doctor before starting any supplement.
What NAD+ Is and Why It Matters
NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme found in every living cell. It plays a central role in energy metabolism, helping convert food into usable cellular energy, and it serves as a fuel source for enzymes involved in DNA repair and cellular stress responses, including the much-discussed sirtuins. The key fact driving the entire field: NAD+ levels decline with age in animal models, and there is evidence of similar declines in human tissues. This decline is associated with reduced mitochondrial function, impaired DNA repair, and other hallmarks of aging.
How steep is the decline? The foundational human data comes from Massudi and colleagues (2012, PLoS One), who measured NAD+ in human pelvic skin samples from newborns to age 77. They found NAD+ correlated negatively with age: levels in young adults (ages 30 to 50) were roughly 68% lower than in newborns, and middle-aged adults (51 to 70) were a further roughly 60% lower than the young adults. The broad takeaway repeated across reviews is that by age 50 to 60, tissue NAD+ levels fall to roughly half of youthful levels, though the exact curve depends on tissue, method, and study. Animal work consistently shows the same pattern: less NAD+ with age, less mitochondrial function, worse repair. The logic of supplementation is straightforward: restore NAD+ to youthful levels, and you might restore youthful cellular function. It is a reasonable hypothesis. Reasonable hypotheses still need testing.
What Are NMN and NR?
You cannot simply take NAD+ as a pill and expect it to reach your cells intact. NAD+ is a large molecule with poor oral bioavailability. Instead, the supplement industry sells precursors, compounds your body converts into NAD+. The two main ones are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside).
The key names to know: Shin-ichiro Imai of Washington University, a pioneer of NAD biology whose group ran the first human NMN trial, and Charles Brenner, now at City of Hope, who discovered in 2004 that NR is a usable NAD+ precursor and has since been one of the most prominent scientific critics of overblown NMN claims. Their disagreement is a useful signal: the NAD biology is legitimate, but the supplement marketing is not science.
Both NMN and NR have been shown in human trials to raise NAD+ levels in blood. That part is established. Multiple randomized, placebo-controlled studies have demonstrated that oral NMN and NR increase circulating NAD+ metabolites in a dose-dependent manner. If the goal is “raise NAD+,” these compounds do what they claim. The much harder question is whether raising NAD+ improves anything that matters.
“The gap between ‘raises a blood marker’ and ‘makes you age slower’ remains unbridged.”
The Human Trials: Raised NAD+, Unclear Benefits
The first randomized human NMN trial was published in Science in 2021 by Yoshino, Klein, and Imai at Washington University. Twenty-five postmenopausal women with prediabetes were randomized to 250 mg of NMN daily or placebo for 10 weeks. The NMN group showed improved insulin sensitivity in skeletal muscle, measured by the gold-standard glucose clamp technique, plus improved expression of genes involved in muscle structure and remodeling. But the trial did not move blood glucose, blood pressure, blood lipids, liver insulin sensitivity, or inflammatory markers. It was small, narrow, and tissue-specific, but it was the first controlled human evidence that NMN does something measurable beyond raising a blood marker.
A 2023 multicenter trial by Yi and colleagues (GeroScience) tested NMN in 80 healthy middle-aged adults aged 40 to 65, randomized to 300 mg, 600 mg, or 900 mg daily or placebo for 60 days. Blood NAD concentrations rose dose-dependently in all NMN groups. The 600 mg and 900 mg groups walked significantly farther in the six-minute walking test than placebo at both 30 and 60 days, and all three NMN groups reported significantly higher general health scores on the SF-36 questionnaire. No safety issues emerged at any dose, including 900 mg daily. This is the most encouraging functional result in humans so far, though walking distance over 60 days is a long way from slowed aging.
Smaller trials fill out the picture. Liao and colleagues (2021, Journal of the International Society of Sports Nutrition) gave amateur runners 300, 600, or 1,200 mg of NMN daily for six weeks: aerobic capacity improved at the 600 and 1,200 mg doses, attributed to better oxygen utilization in muscle. Irie and colleagues (2020) established basic safety in 10 healthy men with single doses of 100, 250, and 500 mg. Katayoshi and colleagues (2023) found 250 mg/day for 12 weeks in healthy adults was well tolerated and trended toward reduced arterial stiffness (pulse wave velocity).
The pattern across all of them: NMN reliably does the biochemical thing it is supposed to do, and there are hints of functional benefit, but nothing approaching proof that it slows human aging. No human trial has demonstrated extended lifespan or clearly slowed aging, and given the timescales involved, none could have yet. A fair summary of the human evidence: the gap between “raises a blood marker” and “makes you age slower” remains unbridged.
What the 2026 Trials Added
The short answer: NMN reliably raises blood NAD+ levels in humans, but no trial shows it extends lifespan or slows aging in any measured way. A September 2026 randomized trial of 62 adults taking 1,250 mg daily for 24 weeks raised NAD 3.6-fold with no gains in strength, walking, hearing, or glucose control. Higher NAD is a biomarker change, not a benefit.
The headline trial of the year was published September 25, 2026: a randomized, double-blind, placebo-controlled study of 62 healthy Japanese adults aged 65 or older, 58 of whom completed it. The NMN group took 1,250 mg daily for 24 weeks and finished with 3.6 times the circulating NAD of baseline. On the outcomes that matter, strength, walking ability, hearing, cardiopulmonary function, blood glucose, and HbA1c, there was no significant benefit. Adverse events ran similar to placebo, though one NMN participant had asymptomatic liver-enzyme elevations, and three authors worked for the company that supplied the NMN.
The broadest look came from a systematic review and meta-analysis in Nutrients covering 15 randomized controlled trials through May 2026, doses from 250 to 2,000 mg per day, durations from 14 days to 24 weeks. The verdict: short-term NMN was well tolerated with no increase in adverse events or liver-enzyme abnormalities, but there were no significant effects on body weight, BMI, fasting glucose, HbA1c, lipid profiles, or systolic blood pressure. Diastolic blood pressure dipped slightly and insulin resistance trended down, which the authors called preliminary vascular-metabolic signals, not proof of anti-aging.
The regulatory story also resolved in 2026. In November 2022 the FDA had concluded NMN was excluded from the legal definition of a dietary supplement because a drug company had started investigating it as a drug first. After a citizen petition and lawsuit from the Natural Products Association, the FDA reversed itself on September 29, 2025, concluding NMN had been sold as a supplement in the United States as early as 2017, before the drug investigation, and confirming in December 2025 letters that it is not excluded from the supplement definition. Legal to sell does not mean proven to work, but the gray zone that had Amazon pulling NMN listings in 2023 is over.
Before you buy, compare the delivery routes: our NAD IV therapy vs NMN compared guide breaks down the infusion-versus-capsule question, and our supplement evidence review runs the same honest filter over the whole category. I also track what supplements actually cost over time, see how my own stack prices moved from 2021 to 2026, before spending on any new bottle.
Safety: Reassuring So Far, With Asterisks
Short-term human trials have generally found NMN and NR well tolerated, with side effect profiles similar to placebo. That is reassuring for a supplement category. The asterisks matter, though. Long-term safety data in humans is essentially nonexistent. Some researchers have raised theoretical concerns worth taking seriously: NAD+ fuels cellular processes including DNA repair, but it also fuels all cells, and there are open scientific questions about whether raising NAD+ could influence processes involved in cancer biology. These are hypotheses, not findings, but they illustrate why “it raises a natural molecule” is not the same as “it is safe forever.”
There is also a regulatory wrinkle. In November 2022, the FDA stated that NMN could not be marketed as a dietary supplement because it had been authorized for investigation as a new drug, a status that triggers exclusion under US supplement law. Industry petitions followed, and the agency’s position has been under review since. Regulatory whiplash is never a confidence builder.
“You are paying premium prices for a promising hypothesis.”
The Cost Question
NMN and NR are expensive relative to most supplements, with quality products often costing many times more than basic vitamins. Given that the proven benefit in humans is currently limited to raising a blood biomarker, with only hints of functional improvement from small trials, the cost-benefit math is unfavorable for most people right now. You are paying premium prices for a promising hypothesis. This is worth stating plainly because the marketing rarely does. When evaluating the evidence behind popular supplements, price should scale with proof, and here the proof has not caught up with the price.
If you are also weighing the clinic route against capsules, my NAD IV therapy vs NMN comparison breaks down the per-session costs, protocols, and evidence side by side.
“Interesting is not the same as effective.”
What Longevity Scientists Actually Think
The serious scientific view is more measured than either the hype or the dismissal. Most aging researchers consider NAD+ biology a legitimate and important research area. Many are cautiously optimistic that it will eventually yield real interventions. Very few would tell you the current evidence justifies expensive daily supplementation for longevity, because the human efficacy data is not there yet. Watch the large, long-term trials currently underway. If NMN or NR shows durable improvements in hard outcomes like physical function, metabolic disease progression, or cardiovascular events, the calculus changes. Until then, this is a “watch the research” category, not a “buy the bottle” category.
The Human Trials, One by One
Filter the trials that matter. Green cards found a positive signal, gray cards found none, blue cards raised NAD without a functional result.
Human randomized trials only, through October 2026. For information only, not medical advice. Talk to your doctor before changing anything.
Where This Fits Among Longevity Strategies
Compared with longevity interventions with real human data, like exercise, maintaining healthy weight, and not smoking, NAD+ precursors are speculative. The fundamentals have effect sizes measured in years of life. NMN has effect sizes measured in blood markers and six-minute walking tests. That comparison should anchor every purchasing decision. Even rapamycin, backed by the strongest animal data in the field, stumbled in its most visible human case, when Johnson quit rapamycin after five years of self-experimentation.
It is the same pattern we found with metformin: a plausible mechanism and years of enthusiasm, but human trials that still have not delivered the longevity outcome people are paying for.
The Bottom Line
NMN and NAD+ precursors do raise NAD+ levels in humans, and the animal research is genuinely promising. But no human evidence shows they slow aging or extend healthy life, long-term safety is unproven, and the products are expensive. This is one of the most interesting areas in longevity science and one of the least proven purchases in the supplement aisle. Interesting is not the same as effective. Wait for the human data.
Sources
- Massudi, H. et al. “Age-associated changes of NAD+ metabolism in human skin.” PLoS One, 2012. (human skin samples: NAD+ declined with age; ~68% lower in young adults vs newborns, ~60% further lower in middle age vs young adults)
- Yoshino, M., Klein, S., Imai, S. et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science, 2021. (n=25 postmenopausal women with prediabetes, 250 mg/day x 10 weeks: improved skeletal muscle insulin sensitivity; no change in blood glucose, BP, or lipids)
- Yi, L. et al. “The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.” GeroScience, 2023. (n=80, ages 40-65, 300/600/900 mg/day x 60 days: dose-dependent NAD increase, improved 6-minute walk distance, higher SF-36 scores, safe to 900 mg/day)
- Liao, B. et al. “Supplemental nicotinamide mononucleotide (NMN) augments aerobic capacity in amateur runners.” Journal of the International Society of Sports Nutrition, 2021. (300/600/1200 mg/day x 6 weeks: aerobic capacity improved at 600 and 1,200 mg)
- Irie, J. et al. 2020 single-dose safety study (n=10 healthy men, 100/250/500 mg: safe, well tolerated)
- Key researchers: David Sinclair (Harvard; popularized NMN, author of Lifespan); Shin-ichiro Imai (Washington University; NAD biology pioneer, co-authored the 2021 Science trial); Charles Brenner (City of Hope; discovered NR as an NAD+ precursor, 2004; prominent critic of NMN marketing claims); Samuel Klein (Washington University; senior investigator on the 2021 trial).
Frequently Asked Questions
Does NMN extend lifespan in humans?
No human trial has shown that. NMN reliably raises blood NAD+ levels, and some small trials found metabolic or recovery signals, but no study has demonstrated longer life, slower aging, or consistent functional improvement. The strongest 2026 evidence, a 24-week randomized trial and a 15-trial meta-analysis, separates the biomarker from the benefit.
Is NMN legal to buy in 2026?
Yes, in the United States. The FDA reversed its 2022 exclusion in a September 29, 2025 decision, concluding NMN had been marketed as a supplement since at least 2017, before the drug investigation that triggered the original ruling. December 2025 letters confirmed manufacturers’ reinstated status. Lawful supplement status is not the same as proven efficacy.
What NMN dose do the trials actually use?
Studied doses range from 250 mg to 2,000 mg per day, with most trials in the 250 to 1,250 mg band and durations from two weeks to six months. There is no established treatment dose, because no trial has established a treatment effect. Doses on store shelves are marketing decisions, not clinical ones.
Is NMN safe?
Short-term, the data is reassuring: a 2026 meta-analysis of 15 randomized trials found no increase in overall or serious adverse events and no liver-enzyme signal. One participant in the September 2026 trial had asymptomatic liver-enzyme elevations. Long-term safety beyond six months is unstudied, and that is the honest gap.
Should I take NMN or NR?
Both are NAD+ precursors and 2026 head-to-head data indicates both roughly double whole-blood NAD+ within about two weeks. Neither has shown a functional longevity benefit in humans. Pick based on price and trial data you trust, not on marketing that implies one has cracked aging.
